Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
608 results about "Wasting" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In medicine, wasting, also known as wasting syndrome, refers to the process by which a debilitating disease causes muscle and fat tissue to "waste" away. Wasting is sometimes referred to as "acute malnutrition" because it is believed that episodes of wasting have a short duration, in contrast to stunting, which is regarded as chronic malnutrition. According to the latest UN estimates, an estimated 52 million children under 5 years of age, or 8%, were wasted in 2011. The vast majority, about 70%, of the world's wasted children live in Asia, most in South-Central Asia.
Formulations comprising selective androgen receptor modulators
InactiveUS6838484B2Decreased libidoAlteration in mood and cognitionBiocideOrganic chemistryDiseaseAging male
The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; and / or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.
Owner:UNIV OF TENNESSEE RES FOUND
4-Aminoquinoline compounds
The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:DEVITA ROBERT J +5
Synthesis of selective androgen receptor modulators
InactiveUS6995284B2Decreased libidoAlteration in mood and cognitionOrganic active ingredientsCarbamic acid derivatives preparationAging maleProstate cancer incidence
The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
Owner:UNIV OF TENNESSEE RES FOUND
Formulations comprising selective androgen receptor modulators
InactiveUS20060004042A1Reduce incidenceDecreasing regressionBiocideAmide active ingredientsDiseaseProstate cancer incidence
The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; and / or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.
Owner:UNIV OF TENNESSEE RES FOUND
Novel activin receptor and uses thereof
The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
Owner:AMGEN INC
Variant activin receptor polypeptides
Owner:AMGEN INC
Synthesis of selective androgen receptor modulators
InactiveUS20060009529A1Decreased libidoAlteration in mood and cognitionBiocideOrganic active ingredientsDiseaseProstate cancer incidence
The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
Owner:UNIV OF TENNESSEE RES FOUND
2-Aminoquinoline compounds
The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:MERCK SHARP & DOHME CORP
Selective androgen receptor modulators for treating muscle wasting
InactiveUS20070161608A1Improving lipid profileImproved profileBiocidePeptide/protein ingredientsSelective androgen receptor modulatorDisease
Owner:UNIV OF TENNESSEE RES FOUND
Solid forms of a JNK inhibitor
The present invention provides solid forms of Compound (I), pharmaceutical compositions thereof, and methods for the treatment or prevention of diseases including, but not limited to a liver disease, cancer, a cardiovascular disease, a metabolic disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension, ischemia / reperfusion injury, central nervous system (CNS) injury / damage or a disease treatable or preventable by the inhibition of JNK. In particular, the invention relates to certain novel crystal forms of the compound 1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy)benzene.
Owner:CELGENE CORP
Indazole compounds and methods of use thereof
InactiveUS20060004043A1Modulating levelUseful in treatmentAntibacterial agentsBiocideAutoimmune conditionProtein kinase A signaling
This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.
Owner:BHAGWAT SHRIPAD S +10
2-Aminoquinoline compounds
The present invention is concerned with compounds of the general Formula I:and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.
Owner:MERCK SHARP & DOHME CORP
Selective androgen receptor modulators
Owner:UNIV OF TENNESSEE RES FOUND
Wireless charging and power supply method for wireless sensor network node
InactiveCN102157988AExtend your lifeAvoid energy consumptionEnergy efficient ICTBatteries circuit arrangementsWireless mesh networkCoupling
The invention discloses a wireless charging and power supply method for a wireless sensor network node. A wireless electrical energy transmission system consisting of a charging and power supply host and a node charging and power supply slave is involved, wherein the charging and power supply host is provided with an energy transmission circuit which has adjustable transmission frequency and power, measurable transmission current and a rotary transmission antenna; and the node charging and power supply slave is provided with a wireless coupling receiving circuit, a multidirectional coupling receiving antenna, a charging and power supply voltage detection circuit and a booster circuit. Optimal coupling frequency and optimal transmission power between the transmission circuit and the receiving circuit are found by scanning the transmission frequency and detecting the detection current, an optimal coupling direction between the transmission antenna and the receiving antenna is found by rotating a charging and power supply antenna, and charging and power supply information is exchanged by a wireless communication channel to determine whether charging and power supply are required or not between the host and the slave and determine charging and power supply frequency and power and the direction of the transmission direction. Therefore, the wasting of idle energy sources is avoided when the slave is not charged and supplied with power, and high wireless charging and power supply efficiency, long wireless charging and power supply distance and high wireless charging and power supply speed are ensured.
Owner:SOUTHEAST UNIV
Push-to-X over cellular coordinated floor and packet scheduling
InactiveUS20060126635A1Network topologiesTime-division multiplexPacket schedulingCommunication device
This coordinated floor and packet scheduling for Push-to-X over Cellular (PoC) services delays a packet data slot assignment until after a PoC floor has been granted (272) by a PoC server (251). By reducing the time period between slot assignment and floor grant, this method reduces the wasting of packet data network resources while the communication device (211) is waiting for a PoC floor grant. Setting up a Push-to-X over Cellular (PoC) call session includes an originating communication device (211) transmitting a PoC floor request message (270) to a PoC server (251), the PoC server (251) sending a PoC floor grant message (272) with treatment type âfloor grantâ to a packet control function, (232), the packet control function (232) assigning packet data slots to the originating communication device and setting up an active packet data session (280), and communicating a PoC floor grant and packet data slot assignment message (285) to the originating communication device (211).
Owner:MOTOROLA INC +1
Selective androgen receptor modulators
The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement and / or other clinical therapeutic and / or diagnostic areas.
Owner:UNIV OF TENNESSEE RES FOUND
Compositions and methods for the treatment of muscle wasting
ActiveUS20080119426A1Improve muscle massQuality improvementGenetic material ingredientsFermentationGeneOligonucleotide
The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and / or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the treatment of muscle wasting conditions and / or the promotion of muscle growth.
Owner:LAKEWOOD AMEDEX
Selective androgen receptor modulators
InactiveUS20060276540A1Reduce incidenceDecreasing regressionBiocideOrganic chemistryDiseaseAging male
The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia,osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas.
Owner:UNIV OF TENNESSEE RES FOUND
Solanaceous vegetable seedling medium prepared by taking vegetable waste compost as fertilizer source and preparation method of solanaceous vegetable seedling medium
InactiveCN104725085AShorten the maturity cycleLoose textureBio-organic fraction processingExcrement fertilisersLivestock manureMicrobial agent
The invention discloses a preparation method of preparing a solanaceous vegetable seedling medium by taking vegetable waste compost as a fertilizer source. According to the preparation method, vegetable waste is taken as a main raw material, crop straws and livestock manure are taken as auxiliary materials, a vegetable waste compost fertilizer is prepared by virtue of forced ventilation static composting and aerobic high temperature biological fermentation, the vegetable waste compost fertilizer, turf, vermiculite and perlite are adequately mixed in a certain volume ratio, a functional microbial agent is added into each mass of mixture, and the solanaceous vegetable seedling medium is prepared; the solanaceous vegetable seedling medium is good in permeability, water retention and fertilizer retention and balanced and reasonable in nutrient supply, the balance requirements of solanaceous vegetable crops to nutrient elements in seedling and growing stages can be met without adding any inorganic chemical fertilizer, and the survival rate and stress resistance of seedlings can be obviously increased; the harmless and resourceful treatment of vegetable waste are achieved, and the huge wasting of vegetable waste and environmental pollution are avoided; the preparation method has wide application value.
Owner:CHINA AGRI UNIV
Filling station for water-based toys
InactiveUS8037906B1Prevent slidingPrevent tippingAmusementsAquatic toysWater basedPolyvinyl chloride
An apparatus designed to fill multiple water balloons and other water-based toys at the same time is herein disclosed. The apparatus takes the form of a large stand approximately thirty-four (34) inches high and twenty-four (24) inches wide made using polyvinylchloride (PVC) piping and fittings. The apparatus is supported across the bottom using two (2) âTâ-shaped legs, also made of PVC pipe. A water connection to a standard garden hose is provided on one (1) leg near the bottom. Four (4) angled valves are provided across a top portion, such that up to four (4) users can use the apparatus simultaneously to refill water-based toys such as squirt guns or water balloons. When finished at each station, each user can easily turn off an individual valve, thus avoiding the wasting of water.
Owner:GRILLO EDWARD J
Selective androgen receptor modulators
The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas.
Owner:UNIV OF TENNESSEE RES FOUND
Method and device for application program starting authentication
ActiveCN105095746AImprove experienceAvoid Privacy LeakageDigital data authenticationPasswordApplication software
The invention provides a method for application program starting authentication, which mainly comprises the steps that an event starting notice sent by a preset backstage service is received, wherein the event starting notice is generated based on a starting behavior of an application program intercepted by the backstage service; a response is made to the event starting notice, a locking interface is started to receive password input of a user, and the authentication is carried out to the starting behavior of the application program; and the backstage service is informed by an authentication result to release or prohibit starting of the application program. In addition, the invention also provides a device for the application program starting authentication. The method and the device for the application program starting authentication provided by the invention can realize locking before the self-starting of the application program, and determine whether the starting is realized by the user's authentication, so that the problem about frame blinking during the locking is solved, time wasting caused by timed polling of a CPU is avoided, and a program locking function with better user experience is realized.
Owner:BEIJING QIHOO TECH CO LTD
Data transmission method and controller
ActiveCN105763416AAvoid wastingImprove resource utilizationNetworks interconnectionTraffic capacityNetwork packet
The embodiment of the invention provides a data transmission method and a controller, so that the resource utilization rate is improved and the resource wasting is prevented. The method comprises: a first data packet, reported by a source network device, of a flow is received; according to the first data packet, a destination network device is determined; VXLAN tunnel forwarding flow tables are issued to the source network device and the destination network device respectively, wherein the VXLAN tunnel forwarding flow tables are used for guiding the network devices to carry out v packaging and forwarding on received follow-up data packets of the flow; VXLAN packaging is carried out on the first data packet and the first data packet after the VXLAN packaging is returned to the source network device, so that the source network device sends the first data packet after the VXLAN packaging to the destination network device. Therefore, on the basis of unified management and control by a controller, the resource utilization rate is improved and the resource wasting is prevented.
Owner:NEW H3C TECH CO LTD
Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals
Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and / or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.
Owner:BAKER DONALD J
Software upgrading method and system
InactiveCN102236563ASave disk spaceSave network bandwidthProgram loading/initiatingTransmissionSoftware engineeringClient-side
The invention discloses a software upgrading method and a software upgrading system, which are used for solving the technical problem that a user machine environment and a user behavior history are not taken into account in the conventional software upgrading method to cause the wasting of a disk space and network bandwidth. In the method and the system, the user machine environment and user behavior historical records are collected, a server generates a local upgrading list for client software according to the machine environment with the client software and the behavior likes and dislikes of a user, and the client software is only required to download a software upgrading module suitable for the client software per se according to the local upgrading list for upgrading. By the technical scheme provided by the invention, not only the disk space and the network bandwidth are saved for the user, but also user experiences are improved.
Owner:TENCENT TECH (SHENZHEN) CO LTD
Synthesis of selective androgen receptor modulators
InactiveUS7759520B2Low yieldHighly pure productsBiocideOrganic active ingredientsAging maleProstate cancer incidence
Owner:UNIV OF TENNESSEE RES FOUND
Use of Myostatin (GDF-8) Antagonists for Treatment of Sarcopenia (Age-Related Muscle-Wasting)
InactiveUS20090136481A1Increased activationOrganic active ingredientsPeptide/protein ingredientsMyostatinSarcopenia
Owner:ORICO
Loach compound feed and preparation method thereof
InactiveCN102919569AMeet all nutritional needsSatisfy eating habitsFood processingAnimal feeding stuffFeed conversion ratioRapeseed
The invention discloses loach compound feed and a preparation method thereof. The loach compound feed is prepared from flour, puffed dehulled soybean meal, rapeseed meal, cottonseed meal, fish meal, peanut meal, distiller's corn meal, rice bran, soybean oil, soybean phospholipid oil, choline chloride, ammonia absorber zeolite, monocalcium phosphate, table salt, a compound pre-mixing agent for crucian and an aquatic product bacillus feed additive. The loach compound feed as loach special-purpose feed can satisfy all nutritional requirements, satisfy a loach ingestion habit, reduce feed wasting and environmental pollution, improve a water environment, has a high feed conversion rate and a feed coefficient of 1.5 to 1.9, and realizes good vitality of loaches and obvious economic benefits.
Owner:HUAIAN ZHENGCHANG FEED
Selective androgen receptor modulators
Owner:UNIV OF TENNESSEE RES FOUND
Methods of using quantitative lipid metabolome data
Described herein in various embodiments are methods for using quantitative and / or comparative lipid metabolite data, particularly for identifying and interpreting individual metabolomic profiles as indicative of metabolic status. The provided methods, for instance, allow analysis of the likelihood or progression of weight gain or weight loss, growth or wasting, obesity, diabetes, and aging in an individual based on measurements of the measurement of the quantity of one or more lipid biomarkers, profiles of such markers, or ratios of such markers.
Owner:TETHYS BIOSCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
Âİ 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com